Angiogenesis inhibitors overcome tumor induced endothelial cell anergy

Arjan W. Griffioen, Cora A. Damen, Kevin H. Mayo, Annemarie F. Barendsz-Janson, Stefano Martinotti, Geert H. Blijham, Gerard Groenewegen

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


We report here that tumor angiogenesis-mediated endothelial cell (EC) anergy can be overcome by inhibitors of angiogenesis. We found previously that tumor growth, known to be dependent on angiogenesis, results in down- regulation of endothelial adhesion molecules and tumor EC anergy to inflammatory signals. We hypothesized that counteracting angiogenesis induces re-expression of adhesion molecules and normalizes responses to inflammatory cytokines. Here, we present data to show that the angiogenesis inhibitor platelet factor-4 (PF4) is able to prevent basic fibroblast growth factor (bFGF)-induced down-regulation of intercellular adhesion molecule-I (ICAM- I). Furthermore, PF4 restores ICAM-I expression following bFGF-induced down- regulation of ICAM-I. This PF4 effect occurs at the protein level and the RNA level and it has functional impact on leukocyte adhesion. In addition, PF4 overcomes the tumor-induced EC anergy to inflammatory signals such as tumor necrosis factor α (TNFα). Our findings may be the basis of new cancer therapies by combining anti-angiogenic therapy and immunotherapy to decrease blood vessel formation and to increase the effectiveness of inflammatory reactions against tumors.

Original languageEnglish (US)
Pages (from-to)315-319
Number of pages5
JournalInternational Journal of Cancer
Issue number2
StatePublished - Jan 18 1999


Dive into the research topics of 'Angiogenesis inhibitors overcome tumor induced endothelial cell anergy'. Together they form a unique fingerprint.

Cite this